Close Menu

Queen's University Belfast

The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.

The genetic evidence supports a link between migrations and important cultural shifts like the emergence of agriculture or metal tools occurring in parallel.

By Justin Petrone
Almac Diagnostics has moved closer to launching its microarray-based test for stage II colorectal cancer recurrence and plans to debut it in the US sometime next year.

NEW YORK (GenomeWeb News) – Almac today said that it is teaming up with researchers at Queen's University, Belfast to develop pharmacogenomics tests for a variety of cancers.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.